|
gptkbp:instance_of
|
gptkb:drug
|
|
gptkbp:bfsLayer
|
5
|
|
gptkbp:bfsParent
|
gptkb:Genzyme_Genetics
|
|
gptkbp:activities
|
MEK inhibitor
|
|
gptkbp:appointed_by
|
oral tablet
|
|
gptkbp:approves
|
gptkb:FDA
|
|
gptkbp:can_be_used_with
|
gptkb:Dabrafenib
|
|
gptkbp:category
|
Category D
|
|
gptkbp:clinical_trial
|
Phase III
monotherapy or combination therapy
|
|
gptkbp:contraindication
|
severe hepatic impairment
hypersensitivity to trametinib
|
|
gptkbp:developed_by
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:dissolved
|
soluble in DMSO
slightly soluble in water
|
|
gptkbp:duration
|
as directed by physician
|
|
gptkbp:effective_date
|
gptkb:2013
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Trametinib
|
|
gptkbp:indication
|
gptkb:BRAF_V600_E_mutation-positive_melanoma
gptkb:BRAF_V600_K_mutation-positive_melanoma
|
|
gptkbp:ingredients
|
C19 H19 Cl F3 N3 O2 S
|
|
gptkbp:interacts_with
|
CY P3 A4 inducers
CY P3 A4 inhibitors
|
|
gptkbp:is_atype_of
|
L01 E G02
|
|
gptkbp:is_monitored_by
|
cardiac function
liver function tests
|
|
gptkbp:is_used_for
|
treatment of melanoma
|
|
gptkbp:lifespan
|
approximately 5 hours
|
|
gptkbp:manager
|
oral
|
|
gptkbp:market
|
gptkb:stock_market_index
|
|
gptkbp:marketed_as
|
gptkb:Mekinist
|
|
gptkbp:metabolism
|
CY P3 A4
|
|
gptkbp:monitors
|
0 R8 D1 B1 D1 A
|
|
gptkbp:reproduction
|
not recommended
|
|
gptkbp:rounds
|
hepatic
|
|
gptkbp:safety_features
|
generally well tolerated
|
|
gptkbp:side_effect
|
fatigue
nausea
diarrhea
rash
elevated liver enzymes
|
|
gptkbp:status
|
ongoing clinical trials
|
|
gptkbp:targets
|
ME K1
ME K2
|
|
gptkbp:tdp
|
not available
|
|
gptkbp:type_of
|
871700-17-3
|
|
gptkbp:type_of_care
|
important for efficacy
|
|
gptkbp:weight
|
452.88 g/mol
|